Lauren J Lee

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 14:75-86. 2011
  2. pmc Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Diabetes Sci Technol 4:547-57. 2010
  3. doi Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial
    Lauren J Lee
    Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, USA
    Diabetes Res Clin Pract 89:157-66. 2010
  4. pmc Trend analyses of insulin delivery systems in the United States
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Diabetes Sci Technol 5:1116-23. 2011
  5. doi Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States
    Manjiri Pawaskar
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Endocr Pract 18:700-11. 2012
  6. doi Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis
    Lauren J Lee
    Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, USA
    Diabetes Res Clin Pract 87:108-16. 2010
  7. doi Association of blood glucose levels with in-hospital mortality and 30-day readmission in patients undergoing invasive cardiovascular surgery
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, IN, USA
    Curr Med Res Opin 28:1657-65. 2012
  8. doi Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe
    Cliff Molife
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Diabetes Technol Ther 11:529-38. 2009

Detail Information

Publications8

  1. doi Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, IN, USA
    J Med Econ 14:75-86. 2011
    ....
  2. pmc Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Diabetes Sci Technol 4:547-57. 2010
    ..This study assessed the patient- and health-care-system-related factors that predict the initiation of one rapid-acting insulin analog (RAIA) delivery system over another...
  3. doi Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial
    Lauren J Lee
    Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, USA
    Diabetes Res Clin Pract 89:157-66. 2010
    ..To examine changes in patient-reported outcome (PRO) measures in patients with type 2 diabetes (T2DM) on oral agents who initiated insulin (insulin lispro mix 25/75 [LM25] or insulin glargine) in the DURABLE trial (n=580)...
  4. pmc Trend analyses of insulin delivery systems in the United States
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Diabetes Sci Technol 5:1116-23. 2011
    ..Despite potential advantages in insulin pen delivery systems (IPDSs), the percentage of patients using an IPDS is relatively low in the United States...
  5. doi Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States
    Manjiri Pawaskar
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Endocr Pract 18:700-11. 2012
    ..To examine the clinical effectiveness of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus in the United States...
  6. doi Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis
    Lauren J Lee
    Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, USA
    Diabetes Res Clin Pract 87:108-16. 2010
    ..To compare total costs and risk of hypoglycemia in patients with type 2 diabetes (T2D) initiated on NPH insulin versus glargine in a real-world setting...
  7. doi Association of blood glucose levels with in-hospital mortality and 30-day readmission in patients undergoing invasive cardiovascular surgery
    Lauren J Lee
    Eli Lilly and Company, Indianapolis, IN, USA
    Curr Med Res Opin 28:1657-65. 2012
    ....
  8. doi Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe
    Cliff Molife
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Diabetes Technol Ther 11:529-38. 2009
    ..These findings have potential clinical and policy implications for patients, diabetes care providers, and/or payers to make evidence-based decisions regarding ways to facilitate initiation and management of insulin therapy...